Biomarkers in Hereditary Angioedema

Area of Science:

• Biochemistry
• Immunology
• Genetics

Background:

• Biomarkers are essential indicators of biological processes and responses to interventions.
• Currently, few validated biomarkers exist for hereditary angioedema (HAE) diagnosis, disease activity monitoring, or treatment assessment.
• HAE pathophysiology involves complex interactions within the complement, coagulation, and fibrinolysis systems, as well as the vascular endothelium.

Purpose of the Study:

• To review existing and potential biomarkers for hereditary angioedema (HAE).
• To highlight biomarkers that can aid in HAE diagnosis, disease activity monitoring, and treatment efficacy evaluation.
• To discuss the importance of linking biomarkers to HAE pathomechanisms, particularly the bradykinin cascade.

Main Methods:

• Literature review of current and emerging biomarkers for HAE.
• Analysis of pathophysiologic pathways in HAE to identify potential molecular targets.
• Discussion of the role of high-throughput omics technologies in biomarker discovery.

Main Results:

• Several molecular candidates from complement, coagulation, fibrinolysis, and vascular endothelium systems show promise as HAE biomarkers.
• Biomarkers specifically linked to the bradykinin-generating cascade are highly desirable for HAE specificity.
• Omics technologies offer potential for discovering novel HAE biomarkers.

Conclusions:

• Development of validated biomarkers is critical for improving HAE management.
• Future research should focus on validating candidate biomarkers for clinical utility in HAE.
• Targeting HAE-specific pathways, like bradykinin generation, will yield the most effective biomarkers.